MCID: BLD062
MIFTS: 68

Bile Duct Cancer

Categories: Cancer diseases, Gastrointestinal diseases, Liver diseases, Rare diseases

Aliases & Classifications for Bile Duct Cancer

MalaCards integrated aliases for Bile Duct Cancer:

Name: Bile Duct Cancer 12 20 54 42 15
Bile Duct Carcinoma 12 15 17 70
Carcinoma of Extrahepatic Bile Duct 12 70
Extrahepatic Bile Duct Carcinoma 12 15
Extrahepatic Bile Duct Cancer 12 20
Bile Duct Neoplasms 44 70
Malignant Neoplasm of the Extrahepatic Bile Duct 12
Malignant Tumor of Extrahepatic Bile Duct 70
Bile Duct Extrahepatic Carcinoma 54
Ca Extrahepatic Bile Ducts 12
Bile Duct Tumor 12

Classifications:



External Ids:

Disease Ontology 12 DOID:4606 DOID:4682 DOID:4897
ICD9CM 34 156.1
MeSH 44 D001650
ICD10 32 C24.0
UMLS 70 C0005396 C0153453 C0238019 more

Summaries for Bile Duct Cancer

GARD : 20 The following summary is from Orphanet, a European reference portal for information on rare diseases and orphan drugs. Orpha Number: 70567 Definition Cholangiocarcinoma (CCA) is a biliary tract cancer (BTC, see this term) originating in the epithelium of the biliary tree, either intra or extra hepatic. Epidemiology The prevalence is unknown but it accounts for approximately 3% of gastrointestinal tumors and 10-15% of all hepatobiliary malignancies. Clinical description CCA can occur in the intra or extra-hepatic biliary tract. A specific type of extra-hepatic CCA known as a Klatskin tumor (see this term) occurs at the junction where the left and right hepatic bile ducts meet the common bile duct (CBD). It is slightly more prevalent in males than females (1.3:1.0) and usually presents in the fifth to seventh decade of life. Clinical manifestations are not usually noted until an advanced disease stage. Extra-hepatic CCA manifests with signs of cholestasis ( jaundice, pale stools, dark urine, pruritus), malaise, weight loss and/or progressive weakness. Intra-hepatic CCA may present with an abdominal mass or with non-specific symptoms of decreased appetite, weight loss, abdominal pain and malaise. Etiology The etiology is unknown and most cases of CCA occur sporadically. Risk factors include primary sclerosing cholangitis (see this term), secondary sclerosing cholangitis, chronic typhoid carriage, parasitic infections ( Opisthochis viverrini and Clonorchis sinensis ), exposure to thorotrast ( x-ray contrast medium) and choledochal cysts, all of which cause chronic biliary inflammation. Diagnostic methods Diagnosis is suspected on clinical and laboratory findings. Serum carbohydrate antigen (CA) 19-9 is the glycoprotein tumor marker most often used in the diagnosis of CCA. It is found to be elevated in 85% of patients. Increased CEA levels are also noted. Extra-hepatic tumors cause increased levels of alkaline phosphate (ALP), conjugated bilirubin and gamma-glutamyl transpeptidase (GGT) while intra-hepatic have only slightly elevated ALP levels. Abdominal imaging, visualization of the biliary tree and biopsies of the lesion are necessary for diagnosis. Magnetic resonance cholangiopancreatography (MRCP) provides information on intrahepatic metastases, biliary anatomy and tumor extension and is used in the staging of CCA. It has been advocated to replace endoscopic retrograde cholangiopancreatography (ERCP), a more invasive method. Visualization of the biliary tree and samples through brush cytology or bile duct biopsies are obtained with ERCP. A needle biopsy is performed in those with a liver mass. Extra-hepatic CCA is further divided into anatomical subtypes according to the Bismuth classification and a disease stage is given. Ultrasound, and contrast enhanced helical computerized computed tomography (CT) can be used in visualizing the extent of disease. Differential diagnosis Intra-hepatic CCA is often mistaken for metastatic adenocarcinoma. Carcinoma of the gallbladder (see this term), benign strictures and Mirizzi syndrome should be excluded. Management and treatment Surgical resection is the only potentially curative treatment for CCA but recurrences after surgery are frequent. Unfortunately CCA is often diagnosed as unresectable because of local extension and/or metastases. Distal CCA arising from the CBD is often treated by pancreatoduodenectomy. More proximal CCA needs hepatic resection. Palliative management involves biliary drainage by inserting metal stents in the biliary tree to release the blockage. Adjuvant chemotherapy after surgery or palliative chemotherapy for unresectable CCA is indicated. Gemcitabine combined with cisplatin therapy is the standard treatment for unresectable biliary tract cancers, including CCA. Prognosis As proximal CCA is usually not diagnosed until a late stage of disease, prognosis is poor with 5-year survival rates of 20-50% after resection and almost 0% in unresectable tumors. Death is often due to biliary sepsis, cancer cachexia, malnutrition and liver failure.

MalaCards based summary : Bile Duct Cancer, also known as bile duct carcinoma, is related to biliary tract cancer and squamous cell bile duct carcinoma, and has symptoms including nausea and vomiting, constipation and abdominal pain. An important gene associated with Bile Duct Cancer is TP53 (Tumor Protein P53), and among its related pathways/superpathways are ERK Signaling and Developmental Biology. The drugs Celecoxib and Analgesics, Non-Narcotic have been mentioned in the context of this disorder. Affiliated tissues include bile duct, liver and pancreas, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Disease Ontology : 12 A biliary tract cancer that is located in the bile duct.

MedlinePlus : 42 Your liver makes a digestive juice called bile. Your gallbladder stores it between meals. When you eat, your gallbladder pushes the bile into tubes called bile ducts. They carry the bile to your small intestine. The bile helps break down fat. It also helps the liver get rid of toxins and wastes. Bile duct cancer is rare. It can happen in the parts of the bile ducts that are outside or inside the liver. Cancer of the bile duct outside of the liver is much more common. Risk factors include having inflammation of the bile duct, ulcerative colitis, and some liver diseases. Symptoms can include Jaundice Itchy skin Fever Abdominal pain Tests to diagnose bile duct cancer may include a physical exam, imaging tests of the liver and bile ducts, blood tests, and a biopsy. Treatments include surgery, radiation therapy, and chemotherapy. NIH: National Cancer Institute

Wikipedia : 73 Cholangiocarcinoma, also known as bile duct cancer, is a type of cancer that forms in the bile ducts.... more...

Related Diseases for Bile Duct Cancer

Diseases in the Bile Duct Cancer family:

Bile Duct Carcinoma in Situ

Diseases related to Bile Duct Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 597)
# Related Disease Score Top Affiliating Genes
1 biliary tract cancer 32.6 SMAD4 MLH1 MET EGFR
2 squamous cell bile duct carcinoma 32.6 KRT7 KRT19
3 cholangiocarcinoma 32.5 VEGFA TP53 SMAD4 NCAM1 MET KRT7
4 intrahepatic cholangiocarcinoma 32.4 TP53 SMAD4 KRT7 KRT19 EGFR CCND1
5 bile duct cystadenocarcinoma 31.5 KRT7 CEACAM5 AFP
6 gallbladder cancer 31.5 TP53 MLH1 EGFR CEACAM5 CDKN2A
7 in situ carcinoma 31.4 TP53 EGFR CDKN2A CCND1
8 tubular adenocarcinoma 31.2 KRT7 EGFR CEACAM5 AFP
9 cholangitis, primary sclerosing 31.2 KRT7 KRT19 IL6 AFP
10 bile duct cysts 31.2 KRT7 KRT19 CEACAM5 AFP
11 cholecystitis 31.1 TP53 EGFR CDKN2A
12 papillary adenocarcinoma 31.1 TP53 KRT7 KRT19 CEACAM5
13 bile duct adenocarcinoma 30.9 TP53 MIR31 KRT7 KRT19 EGFR CEACAM5
14 pancreatic ductal adenocarcinoma 30.9 VEGFA TP53 SMAD4 MSLN MIR31 EGFR
15 small cell carcinoma 30.8 TP53 NCAM1 KRT7 KRT19 EGFR CDKN2A
16 neuroendocrine carcinoma 30.8 NCAM1 KRT7 KRT19 CEACAM5
17 bile duct adenoma 30.8 TP53 NCAM1 KRT7 KRT19 CDKN2A
18 ulcerative colitis 30.8 SMAD4 MLH1 IL6 CLDN18
19 klatskin's tumor 30.8 TP53 KRT7 KRT19 CEACAM5 AFP
20 liver cirrhosis 30.7 VEGFA TP53 IL6 APC AFP
21 spindle cell sarcoma 30.7 VEGFA KRT7 IL6
22 pancreatic adenocarcinoma 30.7 VEGFA TP53 SMAD4 MET IL6 EGFR
23 adenoma 30.7 TP53 SMAD4 MLH1 KRT7 CDKN2A CCND1
24 adenomyoma 30.7 MLH1 KRT7 CDKN2A
25 cystadenocarcinoma 30.7 VEGFA TP53 KRT7 CEACAM5
26 cystadenoma 30.7 KRT7 CEACAM5 AFP
27 gastrointestinal carcinoma 30.7 TP53 KRT19 IL6 CEACAM5
28 carcinosarcoma 30.7 TP53 KRT7 EGFR CDKN2A
29 neurofibromatosis, type i 30.7 TP53 NCAM1 MLH1 EGFR CDKN2A
30 adenosquamous carcinoma 30.6 TP53 SMAD4 KRT7 KRT19 EGFR CEACAM5
31 bladder cancer 30.6 VEGFA TP53 MLH1 MIR31 KRT19 EGFR
32 kidney cancer 30.6 VEGFA TP53 MET EGFR CDKN2A
33 ampulla of vater cancer 30.6 TP53 SMAD4 KRT7 CEACAM5
34 acinar cell carcinoma 30.6 TP53 SMAD4 KRT7 AFP
35 fibrolamellar carcinoma 30.6 KRT7 KRT19 AFP
36 villous adenoma 30.6 TP53 MLH1 KRT7 CEACAM5 APC
37 appendix adenocarcinoma 30.6 SMAD4 KRT7
38 papilloma 30.5 VEGFA TP53 KRT7 FSCN1 EGFR CDKN2A
39 lynch syndrome 30.5 TP53 SMAD4 MLH1 EGFR CDKN2A CCND1
40 pancreatic ductal carcinoma 30.5 VEGFA TP53 SMAD4 MSLN KRT7 EGFR
41 bile duct disease 30.5 TP53 KRT7 KRT19 IL6 CEACAM5 AFP
42 ovary adenocarcinoma 30.5 VEGFA TP53 SMAD4 KRT7 EGFR CEACAM5
43 leukemia, acute myeloid 30.4 VEGFA TP53 NCAM1 MIR31 IL6 EGFR
44 adenocarcinoma 30.4 VEGFA TP53 SMAD4 MLH1 MET KRT7
45 gastric adenocarcinoma 30.4 TP53 SMAD4 MLH1 CEACAM5 CDKN2A APC
46 renal cell carcinoma, nonpapillary 30.4 VEGFA TP53 MSLN MIR31 MET KRT7
47 mucinous adenocarcinoma 30.4 VEGFA TP53 MLH1 KRT7 KRT19 EGFR
48 biliary tract disease 30.4 VEGFA TP53 KRT7 KRT19 IL6 EGFR
49 esophageal cancer 30.3 VEGFA TP53 SMAD4 MLH1 MIR31 KRT19
50 pancreatic cancer 30.3 VEGFA TP53 SMAD4 MSLN MLH1 MIR31

Graphical network of the top 20 diseases related to Bile Duct Cancer:



Diseases related to Bile Duct Cancer

Symptoms & Phenotypes for Bile Duct Cancer

UMLS symptoms related to Bile Duct Cancer:


nausea and vomiting; constipation; abdominal pain; diarrhea; dyspepsia; icterus; heartburn; gastrointestinal gas

GenomeRNAi Phenotypes related to Bile Duct Cancer according to GeneCards Suite gene sharing:

26 (show all 24)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-1 9.75 MLH1
2 Increased shRNA abundance (Z-score > 2) GR00366-A-107 9.75 SMAD4
3 Increased shRNA abundance (Z-score > 2) GR00366-A-11 9.75 SMAD4
4 Increased shRNA abundance (Z-score > 2) GR00366-A-124 9.75 MLH1
5 Increased shRNA abundance (Z-score > 2) GR00366-A-133 9.75 APC
6 Increased shRNA abundance (Z-score > 2) GR00366-A-135 9.75 KRT7
7 Increased shRNA abundance (Z-score > 2) GR00366-A-177 9.75 CLDN18
8 Increased shRNA abundance (Z-score > 2) GR00366-A-178 9.75 CLDN18
9 Increased shRNA abundance (Z-score > 2) GR00366-A-192 9.75 APC KRT7
10 Increased shRNA abundance (Z-score > 2) GR00366-A-195 9.75 MLH1 SMAD4
11 Increased shRNA abundance (Z-score > 2) GR00366-A-200 9.75 MLH1
12 Increased shRNA abundance (Z-score > 2) GR00366-A-202 9.75 APC
13 Increased shRNA abundance (Z-score > 2) GR00366-A-212 9.75 SMAD4
14 Increased shRNA abundance (Z-score > 2) GR00366-A-25 9.75 SMAD4
15 Increased shRNA abundance (Z-score > 2) GR00366-A-43 9.75 SMAD4
16 Increased shRNA abundance (Z-score > 2) GR00366-A-50 9.75 CLDN18
17 Increased shRNA abundance (Z-score > 2) GR00366-A-57 9.75 CLDN18
18 Increased shRNA abundance (Z-score > 2) GR00366-A-63 9.75 CLDN18
19 Increased shRNA abundance (Z-score > 2) GR00366-A-68 9.75 KRT7
20 Increased shRNA abundance (Z-score > 2) GR00366-A-72 9.75 KRT7
21 Increased shRNA abundance (Z-score > 2) GR00366-A-74 9.75 CLDN18 KRT7
22 Increased shRNA abundance (Z-score > 2) GR00366-A-78 9.75 MLH1
23 Increased shRNA abundance (Z-score > 2) GR00366-A-89 9.75 CLDN18
24 Increased shRNA abundance (Z-score > 2) GR00366-A-91 9.75 KRT7

MGI Mouse Phenotypes related to Bile Duct Cancer:

46 (show all 18)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.45 APC CCND1 CDKN2A CLDN18 EGFR FSCN1
2 endocrine/exocrine gland MP:0005379 10.35 AFP APC CCND1 CDKN2A CLDN18 EGFR
3 digestive/alimentary MP:0005381 10.34 APC CCND1 CDKN2A CLDN18 EGFR IL6
4 immune system MP:0005387 10.34 APC CCND1 CDKN2A CLDN18 EGFR FSCN1
5 mortality/aging MP:0010768 10.3 AFP APC CCND1 CDKN2A EGFR FSCN1
6 integument MP:0010771 10.25 APC CCND1 CDKN2A EGFR FSCN1 IL6
7 embryo MP:0005380 10.2 APC CDKN2A EGFR FSCN1 KRT19 MET
8 liver/biliary system MP:0005370 10.18 AFP APC CDKN2A EGFR IL6 KRT19
9 neoplasm MP:0002006 10.18 AFP APC CCND1 CDKN2A EGFR IL6
10 nervous system MP:0003631 10.18 APC CCND1 CDKN2A CLDN18 EGFR FSCN1
11 craniofacial MP:0005382 10.17 APC CCND1 EGFR KRT19 MET SMAD4
12 limbs/digits/tail MP:0005371 10.04 APC EGFR FSCN1 MET SMAD4 TP53
13 muscle MP:0005369 10.03 APC CDKN2A EGFR IL6 MET SMAD4
14 normal MP:0002873 9.97 APC CCND1 EGFR KRT19 MET MSLN
15 reproductive system MP:0005389 9.9 AFP APC CCND1 CDKN2A EGFR IL6
16 renal/urinary system MP:0005367 9.86 APC EGFR IL6 KRT7 MET SMAD4
17 respiratory system MP:0005388 9.7 CCND1 CDKN2A CLDN18 EGFR FSCN1 IL6
18 skeleton MP:0005390 9.32 APC CCND1 CDKN2A CLDN18 EGFR IL6

Drugs & Therapeutics for Bile Duct Cancer

Drugs for Bile Duct Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 180)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Celecoxib Approved, Investigational Phase 4 169590-42-5 2662
2 Analgesics, Non-Narcotic Phase 4
3 Cyclooxygenase Inhibitors Phase 4
4 Cyclooxygenase 2 Inhibitors Phase 4
5 Anti-Inflammatory Agents, Non-Steroidal Phase 4
6 Omega 3 Fatty Acid Phase 4
7 Ulipristal acetate Phase 4 126784-99-4
8
Arginine Investigational, Nutraceutical Phase 4 74-79-3 6322
9
Paclitaxel Approved, Vet_approved Phase 3 33069-62-4 36314
10
Melphalan Approved Phase 2, Phase 3 148-82-3 4053 460612
11
Capecitabine Approved, Investigational Phase 3 154361-50-9 60953
12
Citalopram Approved Phase 3 59729-33-8 2771
13
Dexetimide Withdrawn Phase 3 21888-98-2
14 Hematoporphyrin Derivative Phase 2, Phase 3
15 Folfirinox Phase 2, Phase 3
16 Albumin-Bound Paclitaxel Phase 3
17 Alkylating Agents Phase 2, Phase 3
18 Cola Phase 3
19 Liver Extracts Phase 3
20 Neurotransmitter Agents Phase 3
21 Antidepressive Agents Phase 3
22 Psychotropic Drugs Phase 3
23 Parasympatholytics Phase 3
24 Serotonin Uptake Inhibitors Phase 3
25 Cholinergic Agents Phase 3
26 Muscarinic Antagonists Phase 3
27 Cholinergic Antagonists Phase 3
28 Antiparkinson Agents Phase 3
29
Serotonin Investigational, Nutraceutical Phase 3 50-67-9 5202
30
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
31
Epirubicin Approved Phase 1, Phase 2 56420-45-2 41867
32
Lenograstim Approved, Investigational Phase 2 135968-09-1
33
Hydroxyurea Approved Phase 2 127-07-1 3657
34
Pemetrexed Approved, Investigational Phase 1, Phase 2 150399-23-8, 137281-23-3 60843 446556
35
Aprepitant Approved, Investigational Phase 2 170729-80-3 151165 6918365
36
Fosaprepitant Approved Phase 2 172673-20-0 219090
37
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
38
Bevacizumab Approved, Investigational Phase 2 216974-75-3
39
Lapatinib Approved, Investigational Phase 2 231277-92-2, 388082-78-8 208908 9941095
40
Octreotide Approved, Investigational Phase 2 83150-76-9 6400441 383414
41
Temoporfin Approved, Investigational Phase 2 122341-38-2
42
Irinotecan Approved, Investigational Phase 2 100286-90-6, 97682-44-5 60838
43
Trifluridine Approved, Investigational Phase 2 70-00-8 6256
44
Olaparib Approved Phase 2 763113-22-0 23725625
45
Durvalumab Approved, Investigational Phase 2 1428935-60-7
46
Dexamethasone Approved, Investigational, Vet_approved Phase 2 50-02-2 5743
47
Floxuridine Approved Phase 2 50-91-9 5790
48
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 2 1177-87-3
49
Heparin Approved, Investigational Phase 2 9005-49-6 772 9812414
50
Ichthammol Approved Phase 2 8029-68-3

Interventional clinical trials:

(show top 50) (show all 177)
# Name Status NCT ID Phase Drugs
1 Prospective, Randomized, Open-label, Controlled Trial of Cyclooxygenase-2 Inhibitor (Celecoxib; Celebrex®) for Adjuvant Anticancer Effect in Patients With Biliary-pancreas Cancer. Unknown status NCT01111591 Phase 4 Cox2 inhibitor (Celecoxib)
2 Effects of Preoperative Immunonutrition on Infectious Complication and Th1/Th2 Differentiation in Patients Undergoing Hepatectomy Completed NCT01256047 Phase 4
3 Covered Versus Uncovered Metal Stents for Management of Distal Malignant Biliary Obstruction? Results of a Randomized Prospective Study. Completed NCT00280709 Phase 4
4 Effects of Preoperative Immunonutrition on Infectious Complication and Th1/Th2 Differentiation in Patients Undergoing Pancreaticoduodenectomy Completed NCT01256034 Phase 4
5 Prospective Randomized Trial Comparing Covered Metal Stents Placed Above and Across the Sphincter of Oddi in Malignant Biliary Obstruction: A Multi-nation, Multi-center Study Completed NCT01041612 Phase 4
6 The Effect of Individualized Precision Therapy Programs in Patients With Biliary Tract Cancer Recruiting NCT02943031 Phase 4
7 Clinical Trial of Adjuvant Chemotherapy Followed by Concurrent Chemoradiotherapy Compared With Adjuvant Chemotherapy Alone in Patients With Gallbladder Carcinoma and Extrahepatic Cholangiocarcinoma Unknown status NCT02798510 Phase 3 capecitabine;gemcitabine
8 Open-label Observational Study of Plastic Cylindrical Fiber Optic Diffuser (Pioneer Optics) in Photodynamic Therapy for the Management of Cholangiocarcinoma. Unknown status NCT01755013 Phase 2, Phase 3
9 A Prospective, Randomized Trial of Early Enteral Feeding After Pylorus Preserving Pancreatoduodenectomy Unknown status NCT00809081 Phase 3
10 A Randomised Clinical Trial Evaluating Adjuvant Chemotherapy With Capecitabine Compared to Expectant Treatment Alone (Observation) Following Surgery for Biliary Tract Cancer Completed NCT00363584 Phase 3 capecitabine
11 Gemcitabine, Alone or in Combination With Cisplatin, in Patients With Advanced or Metastatic Cholangiocarcinomas and Other Biliary Tract Tumors: A Multicentre, Randomized Phase III Study Completed NCT00262769 Phase 3 cisplatin;gemcitabine hydrochloride
12 Randomized Phase II-III Study of Chemoradiation With Fluorouracil and Cisplatin Versus Chemotherapy (Gemcitabine/Oxaliplatin) in Non Resectable But Non Metastatic Cancer of the Biliary Tract Completed NCT00304135 Phase 2, Phase 3 cisplatin;gemcitabine hydrochloride;oxaliplatin
13 Phase III Multicenter Randomized Study Comparing the Effect of Adjuvant Chemotherapy for Six Months With Gemcitabine-Oxaliplatin 85 mg/m2 (GEMOX 85) to Observation in Patients Who Underwent Surgery for Cancer of the Bile Ducts Completed NCT01313377 Phase 3 gemcitabine hydrochloride;oxaliplatin
14 Porfimer Sodium Photodynamic Therapy Plus Stenting Versus Stenting Alone in Patients With Advanced or Metastatic Cholangiocarcinomas and Other Biliary Tract Tumours: a Multicentre, Randomised, Phase Lll Study Completed NCT00513539 Phase 3 porfimer sodium
15 Randomised Phase II/III Study, Assessing the Safety and Efficacy of Modified Folfirinox Versus Gemcis in Locally Advanced, Unresectable and/or Metastatic Bile Duct Tumours Completed NCT02591030 Phase 2, Phase 3 GEMCIS;mFolfirinox
16 Randomized Study of Early Palliative Care Integrated With Standard Oncology Care Versus Standard Oncology Care Alone in Patients With Incurable Lung or Non-Colorectal Gastrointestinal Malignancies Completed NCT02349412 Phase 3
17 Phase III Randomized Controlled Trial of a Collaborative Care Intervention to Manage Cancer Related Symptoms in Patients Diagnosed With Hepatobiliary Carcinoma Completed NCT01640522 Phase 3
18 A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers Recruiting NCT03768414 Phase 3 Cisplatin;Gemcitabine Hydrochloride;Nab-paclitaxel
19 Impact of Early Palliative Care on Overall Survival of Patients With Metastatic Upper Gastrointestinal Cancers, Treated With First-line Chemotherapy: a Randomized Phase III Trial Recruiting NCT02853474 Phase 3
20 Randomized, Controlled Study to Compare the Efficacy, Safety and Pharmacokinetics of Melphalan/HDS Treatment Given Sequentially Following Cisplatin/Gemcitabine Versus Cisplatin/Gemcitabine in Patients With IntraHepatic Cholangiocarcinoma Active, not recruiting NCT03086993 Phase 2, Phase 3 Cisplatin and Gemcitabine
21 A Phase III Study of Gemcitabine Plus Capecitabine (GEMCAP) Versus Gemcitabine Alone in Advanced Biliary Cancer Terminated NCT00658593 Phase 3 capecitabine;gemcitabine hydrochloride
22 Symptom Management Trial in Cancer Survivors Terminated NCT00387348 Phase 3 escitalopram oxalate;Placebo
23 Comparison Between Two Methods of Bilateral Stenting for Malignant Hilar Obstruction Withdrawn NCT01622803 Phase 3
24 Phase III Randomized Study of Double Plastic Endoprosthesis Insertion With Versus Without Adjuvant Photodynamic Therapy Using Porfimer Sodium as Palliative Treatment in Patients With Unresectable Stage III-IV Cholangiocarcinoma Withdrawn NCT00253617 Phase 3 porfimer sodium
25 Open One-Arm Therapy Optimizing Trial on Regional Chemotherapy of the Liver Through an Interventionally Implanted A.Hepatica Port System in Patients With Liver Metastases or Primary Liver Neoplasms. Unknown status NCT00356161 Phase 2
26 Study Of Gemcitabine, Leukovorin, And Fluorouracil Used To Treat Locally Advanced And Metastatic Pancreatic And Biliary Adenocarcinomas Unknown status NCT00010088 Phase 2 fluorouracil;gemcitabine hydrochloride;leucovorin calcium
27 Phase II Study of TLC D-99 for Hepatobiliary Carcinomas Unknown status NCT00003296 Phase 2 pegylated liposomal doxorubicin hydrochloride
28 A Phase II, Open-label, Single-arm Study of Photodynamic Laser Therapy Using Foscan for Non-curatively-resectable Bile Duct Carcinoma Unknown status NCT01016002 Phase 2 Temoporfin
29 A Randomized, Open, Prospective Clinical Research Programs of Fluorouracil Implant (Sinofuan) to Improve Surgical Gallbladder Cancer and Bile Duct Cancer Unknown status NCT01317069 Phase 2 Fluorouracil implant
30 Phase II Study to Evaluate the Efficacy of a Chemotherapy Combination With Imatinib (Glivec®) and 5-FU/Leucovorin in Patients With Advanced Carcinoma of the Gallbladder and Bile Duct Completed NCT01153750 Phase 2 Glivec
31 A Phase II Trial of Gemcitabine (NSC-613327) and Capecitabine (NSC-712807) in Patients With Unresectable or Metastatic Gallbladder or Cholangiocarcinoma Completed NCT00033540 Phase 2 capecitabine;gemcitabine hydrochloride
32 A Phase II Study of Intravenous DX-8951f Administered Daily for Five Days Every Three Weeks to Patients With Biliary Tree Cancer (Cholangiocarcinoma and Gallbladder Cancer) Completed NCT00005938 Phase 2 exatecan mesylate
33 A Phase II Study of Gemcitabine in Combination With Capecitabine in Advanced Cholangiocarcinoma Completed NCT00084942 Phase 2 capecitabine;gemcitabine hydrochloride
34 Phase II Study of Photodynamic Therapy With PHOTOFRIN (Porfimer Sodium) for Injection in Patients With Malignant Bile Duct Obstruction Completed NCT00003923 Phase 2 porfimer sodium
35 A Phase II Trial of Dolastatin-10 (NSC 376128) Administered as an IV Bolus Every 3 Weeks in Patients With Hepatobiliary Cancer Completed NCT00003557 Phase 2 dolastatin 10
36 Phase II Trial of 2-Fluorouracil Recombinant Alpha-2a-Interferon and Intravenous Hydroxyurea With Filgrastim in Patients With Refractory GI Malignancies Grant Application Title: Parenteral Hydroxyurea: A Modulator in Pancreatic Cancer Completed NCT00019474 Phase 2 fluorouracil;hydroxyurea
37 Phase II Trial Of Gemcitabine, 5-Fluorouracil, And Leucovorin In Patients With Measurable Unresectable Or Metastatic Biliary Tract Carcinoma (Intrahepatic, Extrahepatic, Ampulla Of Vater) And Gallbladder Carcinoma Completed NCT00009893 Phase 2 fluorouracil;gemcitabine hydrochloride;leucovorin calcium
38 Capecitabine And Gemcitabine In Patients With Advanced Or Metastatic Biliary Tract Cancer, A Multicenter Phase II Trial Completed NCT00073905 Phase 2 capecitabine plus gemcitabine
39 Phase I/II Trial Of Gemcitabine And ALIMTA In Patients With Measurable Or Evaluable, Unresectable Or Metastatic Biliary Tract Carcinoma (Intrahepatic, Extrahepatic, Ampulla Or Vater) And Gallbladder Carcinoma Completed NCT00059865 Phase 1, Phase 2 gemcitabine hydrochloride;pemetrexed disodium
40 A Phase II Trial of Adjuvant Capecitabine/Gemcitabine Chemotherapy Followed By Concurrent Capecitabine and Radiotherapy in Extrahepatic Cholangiocarcinoma (EHCC) Completed NCT00789958 Phase 2 capecitabine;gemcitabine hydrochloride
41 A Feasibility Study to Discern the Tolerability of 5-FU/Gemcitabine Based Chemotherapy Concurrent With Upper Abdominal Radiation and the Utility of Aprepitant/5HT-3 Antagonist (EMEND) for the Prevention of ChemoRadiation-Induced Nausea and Vomiting (CRINV) Completed NCT01534637 Phase 2 aprepitant;gemcitabine hydrochloride;capecitabine;fluorouracil
42 A Phase II Study of Gemcitabine and Cisplatin Plus Sorafenib in Patients With Advanced Biliary Tract Carcinomas Naïve to Systemic Therapy Completed NCT00919061 Phase 2 Gemcitabine;Cisplatin;Sorafenib
43 A Phase II Study of Cabozantinib (XL-184) Monotherapy in Patients With Advanced Cholangiocarcinoma After Progression on First or Second Line Systemic Therapy Completed NCT01954745 Phase 2 Cabozantinib
44 A Pilot Open-Label Clinical Trial of CPI-613 in Patients With Advanced Bile Duct Cancers Completed NCT01766219 Phase 1, Phase 2 6,8-bis(benzylthio)octanoic acid
45 An Open-label, Uncontrolled, Phase II Trial Evaluating the Single-dose and Steady-state Pharmacokinetics of EndoTAG®-1 and Its Effect on the Blood Supply and the Angiogenesis of Hepatic Metastases in Patients With a Carcinomatous Primary Tumor Other Than Hepatocellular (HCC), Biliary or Bile Duct Carcinoma Completed NCT00542048 Phase 2 EndoTAG®-1
46 A Phase II Study of CPT-11 in Patients With Advanced Gallbladder or Bile Duct Tumors Completed NCT00003276 Phase 2 irinotecan hydrochloride
47 A Phase II Trial of OSI-774 in Patients With Hepatocellular or Biliary Carcinoma Completed NCT00033462 Phase 2 erlotinib hydrochloride
48 Phase II Study of BAY 43-9006 (NSC #724772) as Single Agent in Unresectable or Metastatic Gallbladder Carcinoma and Cholangiocarcinoma Completed NCT00238212 Phase 2 sorafenib tosylate
49 A Phase II Trial of Bevacizumab and Erlotinib in Patients With Advanced Biliary Tumors Completed NCT00356889 Phase 2 erlotinib hydrochloride
50 A Phase II Study of Efficacy and Tolerability of GW572016 in Patients With Advanced Hepatocellular and Biliary Carcinomas Completed NCT00107536 Phase 2 lapatinib ditosylate

Search NIH Clinical Center for Bile Duct Cancer

Cochrane evidence based reviews: bile duct neoplasms

Genetic Tests for Bile Duct Cancer

Anatomical Context for Bile Duct Cancer

The Foundational Model of Anatomy Ontology organs/tissues related to Bile Duct Cancer:

19
Bile Duct

MalaCards organs/tissues related to Bile Duct Cancer:

40
Liver, Pancreas, Small Intestine, Lymph Node, Colon, T Cells, Endothelial

Publications for Bile Duct Cancer

Articles related to Bile Duct Cancer:

(show top 50) (show all 2109)
# Title Authors PMID Year
1
Hepatectomy is associated with survival in intrahepatic cholangiocarcinoma: An observational study by instrumental variable analysis. 42
33655908 2021
2
Preoperatively elevated RDW-SD and RDW-CV predict favorable survival in intrahepatic cholangiocarcinoma patients after curative resection. 42
33648470 2021
3
The value of caudate lobectomy in hilar cholangiocarcinoma treatment: A meta-analysis. 42
33607815 2021
4
Significance of mucin expression in pancreatobiliary neoplasms. 54 61
19787286 2010
5
Four primary malignancies successively occurred in a BRCA2 mutation carrier: a case report. 54 61
16982466 2006
6
CDX2 and MUC2 protein expression in extrahepatic bile duct carcinoma. 61 54
16191504 2005
7
Immunohistochemical expression of matrix metalloproteinases in bile duct cancer tissue. 61 54
15682828 2004
8
Down-regulated p16 expression predicts poor prognosis in patients with extrahepatic biliary tract carcinomas. 61 54
11836554 2002
9
Genetic detection for micrometastasis in lymph node of biliary tract carcinoma. 61 54
10873083 2000
10
Expression of collagenase (MMP2), stromelysin (MMP3) and tissue inhibitor of the metalloproteinases (TIMP1) in pancreatic and ampullary disease. 54 61
8611434 1996
11
Neural cell adhesion molecule and perineural invasion in gallbladder cancer. 54 61
7844990 1995
12
Neural cell adhesion molecule (NCAM) and perineural invasion in bile duct cancer. 61 54
8501910 1993
13
[Role of carcinoembryonic antigen, carbohydrate antigen 19-9 and cytology of bile in diagnosis of biliary and pancreatic cancer]. 54 61
1886576 1991
14
Investigation of possible alternate animal reservoir hosts of Opisthorchis viverrini. 61
33524385 2021
15
Adenomyomatous hyperplasia of the extrahepatic bile duct: a systematic review of a rare lesion mimicking bile duct carcinoma. 61
33400191 2021
16
Role of CH-EUS as guidance for EUS-biliary drainage malignant obstruction. 61
33793159 2021
17
Recurrent cholangiocarcinoma with long-term survival by multimodal treatment: A case report. 61
33732458 2021
18
Prognostic Impact of Resection Margin Length in Patients Undergoing Resection for Mid-Common Bile Duct Cancer: A Single-Center Experience. 61
33784683 2021
19
Factors affecting the diagnostic yield of endoscopic transpapillary forceps biopsy in patients with malignant biliary strictures. 61
33729610 2021
20
Cholangiocarcinoma miscoding in hepatobiliary centres. 61
33032867 2021
21
Rapid recurrence of spindle cell type undifferentiated carcinoma early after radical surgery in a bile duct cancer patient - A case report. 61
33756162 2021
22
Foodborne zoonotic parasites of the family Opisthorchiidae. 61
33158552 2021
23
Treatment of jejunal variceal bleeding with portal vein thrombosis after bile duct cancer surgery by short single-balloon endoscope. 61
33660344 2021
24
The prevalence of micronutrient deficiency in patients with suspected pancreatico-biliary malignancy: Results from a specialist Hepato-Biliary and Pancreatic unit. 61
33775486 2021
25
Apigenin protects mice against 3,5-diethoxycarbonyl-1,4-dihydrocollidine-induced cholestasis. 61
33620063 2021
26
Two-way Revascularization to Manage Celiac Artery Stenosis during Pancreaticoduodenectomy: A Case Report. 61
33680671 2021
27
Impact of changes in the topographic classification of Klatskin tumor on incidence of intra- and extrahepatic bile duct cancer: A population-based national cancer registry study. 61
33615747 2021
28
Precision Liver Resection: Three-Dimensional Reconstruction Combined with Fluorescence Laparoscopic Imaging. 61
32873180 2021
29
Liver transplantation for perihilar cholangiocarcinoma: patient selection and outcomes. 61
33577361 2021
30
Outcomes of 5000 pancreatectomies in Korean single referral center and literature reviews. 61
33636051 2021
31
Bile Metabolites and Risk of Carcinogenesis in Patients With Pancreaticobiliary Maljunction: A Pilot Study. 61
33419827 2021
32
Radiologic Evaluation and Structured Reporting Form for Extrahepatic Bile Duct Cancer: 2019 Consensus Recommendations from the Korean Society of Abdominal Radiology. 61
32901457 2021
33
Central hepatopancreatoduodenectomy-oncological effectiveness and parenchymal sparing option for diffusely spreading bile duct cancer: report of two cases. 61
33407366 2021
34
Association between gallstones and the risk of biliary tract cancer: a systematic review and meta-analysis. 61
33541011 2021
35
Chimeric Antigen Receptor T Cells Targeting Integrin αvβ6 Expressed on Cholangiocarcinoma Cells. 61
33763382 2021
36
Reversine, a selective MPS1 inhibitor, induced autophagic cell death via diminished glucose uptake and ATP production in cholangiocarcinoma cells. 61
33505802 2021
37
The clinical significance of preoperative C-reactive protein/albumin ratio in patients with resected extrahepatic bile duct cancer. 61
33387024 2021
38
[A case of distal bile duct carcinoma converted to neuroendocrine cancer and proliferated into the pancreas]. 61
33563857 2021
39
Diagnostic accuracy of administrative database for bile duct cancer by ICD-10 code in a tertiary institute in Korea. 61
32249128 2020
40
A case of stent-graft implantation for postpancreaticoduodenectomy hemorrhage in a patient with a reconstructed gastric tube. 61
33117472 2020
41
Adjuvant and neoadjuvant therapy for biliary tract cancer: a review of clinical trials. 61
33037430 2020
42
Gramicidin inhibits cholangiocarcinoma cell growth by suppressing EGR4. 61
31852273 2020
43
Anti-tumour effect of the fourth-generation chimeric antigen receptor T cells targeting CD133 against cholangiocarcinoma cells. 61
33242709 2020
44
Monitoring the Progression of Liver Fluke-Induced Cholangiocarcinoma in a Hamster Model Using Synchrotron FTIR Microspectroscopy and Focal Plane Array Infrared Imaging. 61
33170647 2020
45
IgG4-related autoimmune liver disease. 61
33267565 2020
46
Hepatitis B virus infection and the risk of cancer among the Chinese population. 61
32478856 2020
47
Therapeutic results of Denver percutaneous peritoneovenous shunt in cancer patients with malignant ascites. 61
33380660 2020
48
Direct visualization of an intraductal papillary neoplasm of the bile duct: A premalignant lesion of bile duct cancer. 61
33262052 2020
49
[18F]-FDG PET/CT in a case of metastatic extrahepatic bile duct cancer from sigmoid carcinoma. 61
33200299 2020
50
Low H3K9me3 Expression Is Associated With Poor Prognosis in Patients With Distal Common Bile Duct Cancer. 61
33144476 2020

Variations for Bile Duct Cancer

Cosmic variations for Bile Duct Cancer:

9 (show top 50) (show all 9120)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM140721366 ZNF521 biliary tract,gallbladder,carcinoma,adenocarcinoma c.835T>C p.S279P 18:25226423-25226423 12
2 COSM94799464 ZNF521 biliary tract,gallbladder,carcinoma,adenocarcinoma c.1495T>C p.S499P 18:25226423-25226423 12
3 COSM94795627 ZNF521 biliary tract,gallbladder,carcinoma,adenocarcinoma c.-1-75G>A p.? 18:25351022-25351022 12
4 COSM131506278 ZNF521 biliary tract,gallbladder,carcinoma,adenocarcinoma c.1495T>C p.S499P 18:25226423-25226423 12
5 COSM131502102 ZNF521 biliary tract,gallbladder,carcinoma,adenocarcinoma c.-47-29G>A p.? 18:25351022-25351022 12
6 COSM140717571 ZNF521 biliary tract,gallbladder,carcinoma,adenocarcinoma c.-621+983G>A p.? 18:25351022-25351022 12
7 COSM125149394 ZFHX4 biliary tract,gallbladder,carcinoma,adenocarcinoma c.4538G>A p.R1513H 8:76851537-76851537 12
8 COSM127376784 ZFHX4 biliary tract,gallbladder,carcinoma,adenocarcinoma c.4616G>A p.R1539H 8:76851537-76851537 12
9 COSM127371571 ZFHX4 biliary tract,gallbladder,carcinoma,adenocarcinoma c.10571A>C p.K3524T 8:76864285-76864285 12
10 COSM125144409 ZFHX4 biliary tract,gallbladder,carcinoma,adenocarcinoma c.10493A>C p.K3498T 8:76864285-76864285 12
11 COSM125186347 ZFHX4 biliary tract,gallbladder,carcinoma,adenocarcinoma c.1738G>T p.G580* 8:76705826-76705826 12
12 COSM127365243 ZFHX4 biliary tract,gallbladder,carcinoma,adenocarcinoma c.*1399G>A p.? 8:76865964-76865964 12
13 COSM125180058 ZFHX4 biliary tract,gallbladder,carcinoma,adenocarcinoma c.*345G>T p.? 8:76864910-76864910 12
14 COSM127406292 ZFHX4 biliary tract,gallbladder,carcinoma,adenocarcinoma c.*345G>T p.? 8:76864910-76864910 12
15 COSM127412310 ZFHX4 biliary tract,gallbladder,carcinoma,adenocarcinoma c.1738G>T p.G580* 8:76705826-76705826 12
16 COSM127412300 ZFHX4 biliary tract,gallbladder,carcinoma,adenocarcinoma c.-71G>A p.? 8:76681596-76681596 12
17 COSM149327014 ZFHX3 biliary tract,gallbladder,carcinoma,adenocarcinoma c.3003G>A p.L1001= 16:72950682-72950682 12
18 COSM87276533 ZFHX3 biliary tract,bile duct,carcinoma,adenocarcinoma c.6964C>T p.R2322* 16:72795718-72795718 12
19 COSM87294455 ZFHX3 biliary tract,gallbladder,carcinoma,adenocarcinoma c.3003G>A p.L1001= 16:72950682-72950682 12
20 COSM87284738 ZFHX3 biliary tract,gallbladder,carcinoma,adenocarcinoma c.*2655C>T p.? 16:72784509-72784509 12
21 COSM102048118 ZFHX3 biliary tract,bile duct,carcinoma,adenocarcinoma c.787+1G>A p.? 16:72829778-72829778 12
22 COSM102045430 ZFHX3 biliary tract,gallbladder,carcinoma,adenocarcinoma c.261G>A p.L87= 16:72950682-72950682 12
23 COSM149332377 ZFHX3 biliary tract,bile duct,carcinoma,adenocarcinoma c.3529+1G>A p.? 16:72829778-72829778 12
24 COSM87296816 ZFHX3 biliary tract,bile duct,carcinoma,adenocarcinoma c.3529+1G>A p.? 16:72829778-72829778 12
25 COSM102025189 ZFHX3 biliary tract,bile duct,carcinoma,adenocarcinoma c.4222C>T p.R1408* 16:72795718-72795718 12
26 COSM149275977 ZFHX3 biliary tract,bile duct,carcinoma,adenocarcinoma c.6964C>T p.R2322* 16:72795718-72795718 12
27 COSM149299892 ZFHX3 biliary tract,gallbladder,carcinoma,adenocarcinoma c.*2655C>T p.? 16:72784509-72784509 12
28 COSM102035174 ZFHX3 biliary tract,gallbladder,carcinoma,adenocarcinoma c.*2655C>T p.? 16:72784509-72784509 12
29 COSM90947216 YAP1 biliary tract,bile duct,carcinoma,adenocarcinoma c.434C>G p.T145S 11:102114256-102114256 12
30 COSM127997056 YAP1 biliary tract,bile duct,carcinoma,adenocarcinoma c.434C>G p.T145S 11:102114256-102114256 12
31 COSM145027300 YAP1 biliary tract,bile duct,carcinoma,adenocarcinoma c.434C>G p.T145S 11:102114256-102114256 12
32 COSM128451074 YAP1 biliary tract,bile duct,carcinoma,adenocarcinoma c.434C>G p.T145S 11:102114256-102114256 12
33 COSM126972057 YAP1 biliary tract,bile duct,carcinoma,adenocarcinoma c.-101C>G p.? 11:102114256-102114256 12
34 COSM85236535 YAP1 biliary tract,bile duct,carcinoma,adenocarcinoma c.434C>G p.T145S 11:102114256-102114256 12
35 COSM143040603 YAP1 biliary tract,bile duct,carcinoma,adenocarcinoma c.434C>G p.T145S 11:102114256-102114256 12
36 COSM133273136 YAP1 biliary tract,bile duct,carcinoma,adenocarcinoma c.434C>G p.T145S 11:102114256-102114256 12
37 COSM104236735 XPO1 biliary tract,bile duct,carcinoma,adenocarcinoma c.729G>T p.E243D 2:61498703-61498703 12
38 COSM104240798 XPO1 biliary tract,bile duct,carcinoma,adenocarcinoma c.273G>T p.W91C 2:61522639-61522639 12
39 COSM101978949 XPO1 biliary tract,bile duct,carcinoma,adenocarcinoma c.338C>T p.T113M 2:61502274-61502274 12
40 COSM101977429 XPO1 biliary tract,bile duct,carcinoma,adenocarcinoma c.729G>T p.E243D 2:61498703-61498703 12
41 COSM104888049 XPO1 biliary tract,bile duct,carcinoma,adenocarcinoma c.273G>T p.W91C 2:61522639-61522639 12
42 COSM104238660 XPO1 biliary tract,bile duct,carcinoma,adenocarcinoma c.338C>T p.T113M 2:61502274-61502274 12
43 COSM104883338 XPO1 biliary tract,bile duct,carcinoma,adenocarcinoma c.729G>T p.E243D 2:61498703-61498703 12
44 COSM101981179 XPO1 biliary tract,bile duct,carcinoma,adenocarcinoma c.273G>T p.W91C 2:61522639-61522639 12
45 COSM104885218 XPO1 biliary tract,bile duct,carcinoma,adenocarcinoma c.338C>T p.T113M 2:61502274-61502274 12
46 COSM91375813 WT1 biliary tract,gallbladder,carcinoma,adenocarcinoma c.1229T>C p.M410T 11:32396277-32396277 12
47 COSM111531901 WT1 biliary tract,gallbladder,carcinoma,adenocarcinoma c.1178T>C p.M393T 11:32396277-32396277 12
48 COSM113478099 WT1 biliary tract,gallbladder,carcinoma,adenocarcinoma c.1229T>C p.M410T 11:32396277-32396277 12
49 COSM147427179 WT1 biliary tract,gallbladder,carcinoma,adenocarcinoma c.441C>T p.G147= 11:32434905-32434905 12
50 COSM149740900 WT1 biliary tract,gallbladder,carcinoma,adenocarcinoma c.441C>T p.G147= 11:32434905-32434905 12

Expression for Bile Duct Cancer

Search GEO for disease gene expression data for Bile Duct Cancer.

Pathways for Bile Duct Cancer

Pathways related to Bile Duct Cancer according to GeneCards Suite gene sharing:

(show all 46)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.82 VEGFA TP53 SMAD4 MET IL6 EGFR
2
Show member pathways
13.49 VEGFA SMAD4 NCAM1 MET KRT7 KRT19
3
Show member pathways
13.33 VEGFA TP53 NCAM1 MET IL6 FSCN1
4
Show member pathways
12.96 VEGFA TP53 MET IL6 EGFR CCND1
5
Show member pathways
12.92 VEGFA TP53 IL6 EGFR CDKN2A CCND1
6
Show member pathways
12.83 VEGFA TP53 SMAD4 MLH1 EGFR CDKN2A
7
Show member pathways
12.7 TP53 SMAD4 MLH1 MET EGFR CDKN2A
8
Show member pathways
12.67 TP53 MET EGFR CDKN2A CCND1
9
Show member pathways
12.59 VEGFA TP53 MET IL6 EGFR CCND1
10 12.58 VEGFA TP53 SMAD4 MLH1 MET IL6
11 12.36 TP53 SMAD4 CDKN2A CCND1 APC
12 12.33 TP53 SMAD4 IL6 CDKN2A CCND1
13
Show member pathways
12.29 TP53 IL6 EGFR CCND1 APC
14 12.28 VEGFA TP53 MET EGFR CCND1
15 12.23 SMAD4 FSCN1 APC AFP
16 12.18 TP53 SMAD4 CCND1 APC
17 12.15 SMAD4 CCND1 APC AFP
18 12.14 TP53 IL6 CDKN2A CCND1
19 12.13 VEGFA TP53 SMAD4 EGFR CCND1
20 12.1 VEGFA TP53 MIR31 MET FSCN1 EGFR
21
Show member pathways
12.07 SMAD4 IL6 EGFR CCND1
22 12.05 TP53 SMAD4 MET CCND1
23 12.01 VEGFA NCAM1 MET KRT19 IL6 AFP
24 12 TP53 IL6 EGFR CCND1
25 11.99 TP53 SMAD4 CDKN2A CCND1 APC
26 11.98 VEGFA TP53 IL6 FSCN1 CCND1
27 11.97 TP53 MLH1 MET EGFR APC AFP
28 11.95 TP53 EGFR CDKN2A CCND1 APC
29 11.94 TP53 SMAD4 IL6 CDKN2A
30 11.91 VEGFA SMAD4 IL6 CCND1
31 11.79 TP53 IL6 AFP
32 11.73 TP53 MLH1 CDKN2A
33 11.72 VEGFA TP53 EGFR CDKN2A CCND1
34 11.71 SMAD4 MET EGFR
35
Show member pathways
11.71 VEGFA EGFR CCND1
36 11.7 TP53 MET EGFR
37 11.69 VEGFA TP53 SMAD4 CDKN2A
38
Show member pathways
11.65 VEGFA IL6 CCND1
39 11.57 VEGFA TP53 CDKN2A
40 11.57 TP53 CCND1 APC
41
Show member pathways
11.44 VEGFA MET EGFR
42 11.44 VEGFA TP53 SMAD4 MLH1 IL6 EGFR
43 11.43 TP53 IL6 EGFR CDKN2A CCND1
44 11.36 VEGFA TP53 SMAD4 IL6 CCND1
45 11.27 SMAD4 MET EGFR APC
46 10.64 VEGFA MIR31

GO Terms for Bile Duct Cancer

Cellular components related to Bile Duct Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 anchored component of membrane GO:0031225 9.26 NCAM1 MSLN CEACAM5 CD24
2 cell surface GO:0009986 9.17 VEGFA NCAM1 MSLN MET EGFR CEACAM5

Biological processes related to Bile Duct Cancer according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription by RNA polymerase II GO:0045944 9.98 VEGFA TP53 SMAD4 MET IL6 EGFR
2 negative regulation of cell proliferation GO:0008285 9.89 TP53 SMAD4 IL6 CDKN2A APC
3 cell adhesion GO:0007155 9.8 NCAM1 MSLN CLDN18 CEACAM5 CD24 APC
4 cytokine-mediated signaling pathway GO:0019221 9.65 VEGFA TP53 IL6 FSCN1 CCND1
5 response to estrogen GO:0043627 9.63 KRT19 CD24 CCND1
6 positive regulation of MAP kinase activity GO:0043406 9.58 VEGFA EGFR CD24
7 mitotic G1 DNA damage checkpoint GO:0031571 9.51 TP53 CCND1
8 positive regulation of extracellular matrix disassembly GO:0090091 9.48 IL6 FSCN1
9 positive regulation of transcription from RNA polymerase II promoter in response to hypoxia GO:0061419 9.37 VEGFA TP53
10 response to UV-A GO:0070141 9.16 EGFR CCND1
11 liver regeneration GO:0097421 9.13 IL6 EGFR CCND1
12 positive regulation of production of miRNAs involved in gene silencing by miRNA GO:1903800 8.8 TP53 IL6 EGFR

Molecular functions related to Bile Duct Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.96 VEGFA TP53 SMAD4 NCAM1 MSLN MLH1
2 identical protein binding GO:0042802 9.76 VEGFA TP53 SMAD4 NCAM1 MET EGFR
3 MDM2/MDM4 family protein binding GO:0097371 9.26 TP53 CDKN2A
4 protein kinase binding GO:0019901 9.1 TP53 EGFR CDKN2A CD24 CCND1 APC

Sources for Bile Duct Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....